Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 6/2018

01-12-2018 | Original Article

Prognostic outcome and complications of sentinel lymph node navigation surgery for early-stage cervical cancer

Authors: Hideaki Yahata, Hiroaki Kobayashi, Kenzo Sonoda, Keisuke Kodama, Hiroshi Yagi, Masafumi Yasunaga, Tatsuhiro Ohgami, Ichiro Onoyama, Eisuke Kaneki, Kaoru Okugawa, Shingo Baba, Takuro Isoda, Yoshihiro Ohishi, Yoshinao Oda, Kiyoko Kato

Published in: International Journal of Clinical Oncology | Issue 6/2018

Login to get access

Abstract

Background

To evaluate the prognostic outcome and surgical complications in patients with early-stage cervical cancer who underwent sentinel node navigation surgery (SNNS) for hysterectomy or trachelectomy.

Methods

A total of 139 patients who underwent SNNS using 99mTc phytate between 2009 and 2015 were evaluated. No further lymph node dissection was performed when intraoperative analysis of the sentinel lymph nodes (SLNs) was negative for metastasis. We compared the surgical complications between the SNNS group and 67 matched patients who underwent pelvic lymph node dissection (PLND) after SLN mapping between 2003 and 2008. We also examined the clinical outcomes in the SNNS group.

Results

The mean number of detected SLNs was 2.5 per patient. Fourteen of the 139 patients in the SNNS group underwent PLND based on the intraoperative SLN results. The amount of blood loss, the operative time, and the number of perioperative complications were significantly less in the SNNS group than in the matched PLND group. There was no recurrence during a follow-up period ranging from 2 to 88 months (median 40 months) in the SNNS group.

Conclusions

Using SNNS for early-stage cervical cancer is safe and effective and does not increase the recurrence rate. A future multicenter trial is warranted.
Literature
1.
Saito T, Takahashi F, Katabuchi H (2017) 2016 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology, annual report of the committee on gynecologic oncology, Japan Society of Obstetrics and Gynecology: patient annual report for 2014 and treatment annual report for 2009. J Obstet Gynaecol Res 43:1667–1677CrossRef
2.
Benedetti-Panici P, Maneschi F, Scambia G et al (1996) Lymphatic spread of cervical cancer: an anatomical and pathological study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy. Gynecol Oncol 62:19–24CrossRef
3.
Fuller AF Jr, Elliott N, Kosloff C et al (1982) Lymph node metastases from carcinoma of the cervix, stages IB and IIA: implications for prognosis and treatment. Gynecol Oncol 13:165–174CrossRef
4.
Bats AS, Mathevet P, Buenerd A et al (2013) The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective SENTICOL study. Ann Surg Oncol 20:413–422CrossRef
5.
van de Lande J, Torrenga B, Raijmakers PG et al (2007)) Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review. Gynecol Oncol 106:604–613CrossRef
6.
Altgassen C, Hertel H, Brandstädt A et al (2008) AGO Study Group. Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO study group. J Clin Oncol 26:2943–2951CrossRef
7.
Niikura H, Okamura C, Akahira J et al (2004) Sentinel lymph node detection in early cervical cancer with combination 99mTc phytate and patent blue. Gynecol Oncol 94:528–532CrossRef
8.
Ogawa S, Kobayashi H, Amada S et al (2010) Sentinel node detection with (99 m) Tc phytate alone is satisfactory for cervical cancer patients undergoing radical hysterectomy and pelvic lymphadenectomy. Int J Clin Oncol 15:52–58CrossRef
9.
Koh WJ, Greer BE, Abu-Rustum NR et al (2015) Cervical cancer, version 2.2015. J Natl Compr Canc Netw 13:395–404CrossRef
10.
Takei H, Suemasu K, Kurosumi M et al (2006) 99mTc-phytate is better than 99mTc-human serum albumin as a radioactive tracer for sentinel lymph node biopsy in breast cancer. Surg Today 36:219–224CrossRef
11.
Jewell EL, Huang JJ, Abu-Rustum NR et al (2014) Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. Gynecol Oncol 133:274–277CrossRef
12.
Imboden S, Papadia A, Nauwerk M et al (2015) A comparison of radiocolloid and indocyanine green fluorescence imaging, sentinel lymph node mapping in patients with cervical cancer undergoing laparoscopic surgery. Ann Surg Oncol 22:4198–4203CrossRef
13.
Buda A, Papadia A, Zapardiel I et al (2016) From conventional radiotracer Tc-99(m) with blue dye to indocyanine green fluorescence: a comparison of methods towards optimization of sentinel lymph node mapping in early stage cervical cancer for a laparoscopic approach. Ann Surg Oncol 23:2959–2965CrossRef
14.
Niikura H, Okamoto S, Otsuki T et al (2012) Prospective study of sentinel lymph node biopsy without further pelvic lymphadenectomy in patients with sentinel lymph node-negative cervical cancer. Int J Gynecol Cancer 22:1244–1250CrossRef
15.
Kim SI, Lim MC, Lee JS et al (2015) Impact of lower limb lymphedema on quality of life in gynecologic cancer survivors after pelvic lymph node dissection. Eur J Obstet Gynecol Reprod Biol 192:31–36CrossRef
16.
Krag DN, Anderson SJ, Julian TB et al (2007) National Surgical Adjuvant Breast and Bowel Project. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8:881–888CrossRef
17.
Veronesi U, Paganelli G, Viale G et al (2006) Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 7:983–990CrossRef
18.
19.
Tsujimoto M, Nakabayashi K, Yoshidome K et al (2007) One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 13:4807–4816CrossRef
20.
Visser M, Jiwa M, Horstman A et al (2008) Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer. Int J Cancer 122:2562–2567CrossRef
21.
Yamamoto H, Sekimoto M, Oya M et al (2011) OSNA-based novel molecular testing for lymph node metastases in colorectal cancer patients: results from a multicenter clinical performance study in Japan. Ann Surg Oncol 18:1891–1898CrossRef
22.
Okamoto S, Niikura H, Nakabayashi K et al (2013) Detection of sentinel lymph node metastases in cervical cancer: assessment of KRT19 mRNA in the one-step nucleic acid amplification (OSNA) method. Gynecol Oncol 130:530–536CrossRef
Metadata
Title
Prognostic outcome and complications of sentinel lymph node navigation surgery for early-stage cervical cancer
Authors
Hideaki Yahata
Hiroaki Kobayashi
Kenzo Sonoda
Keisuke Kodama
Hiroshi Yagi
Masafumi Yasunaga
Tatsuhiro Ohgami
Ichiro Onoyama
Eisuke Kaneki
Kaoru Okugawa
Shingo Baba
Takuro Isoda
Yoshihiro Ohishi
Yoshinao Oda
Kiyoko Kato
Publication date
01-12-2018
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 6/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-018-1327-y

Other articles of this Issue 6/2018

International Journal of Clinical Oncology 6/2018 Go to the issue

Original Article

Phase II study of S-1 plus oxaliplatin 130 mg/m2 in Japanese patients with advanced gastric cancer

Original Article

Serum iron levels increased by cancer chemotherapy correlate the chemotherapy-induced nausea and vomiting

Original Article

A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)

Original Article

Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization

Original Article

Definitive chemoradiotherapy for anal canal cancer: single-center experience

Original Article

Observational study of chemotherapy-induced Clostridium difficile infection in patients with lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits